IDEXX Laboratories, Inc. $IDXX Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 32.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,343 shares of the company’s stock after selling 6,743 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in IDEXX Laboratories were worth $9,164,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of IDEXX Laboratories by 41.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after acquiring an additional 605,290 shares during the period. Generation Investment Management LLP bought a new position in IDEXX Laboratories in the 2nd quarter worth about $304,277,000. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $221,955,000. JPMorgan Chase & Co. raised its holdings in shares of IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the last quarter. Finally, Schroder Investment Management Group raised its holdings in shares of IDEXX Laboratories by 295.1% during the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after buying an additional 235,863 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several analyst reports. BTIG Research lowered their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Activity

In other news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 44,199 shares of company stock worth $28,746,535. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $648.70 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The business’s fifty day moving average is $669.92 and its two-hundred day moving average is $668.75. The stock has a market capitalization of $51.65 billion, a P/E ratio of 49.63, a P/E/G ratio of 3.86 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm earned $2.53 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.